These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 14697416)

  • 1. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
    Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy.
    Bonin SR; Hanlon AL; Lee WR; Movsas B; al-Saleem TI; Hanks GE
    Cancer; 1997 Jan; 79(1):75-80. PubMed ID: 8988729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
    Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
    Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
    Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.
    Kestin LL; Goldstein NS; Vicini FA; Martinez AA
    J Urol; 2002 Nov; 168(5):1994-9. PubMed ID: 12394693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer.
    Beard C; Schultz D; Loffredo M; Cote K; Renshaw AA; Hurwitz MD; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):403-7. PubMed ID: 16765530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE; Hanlon AL; Epstein B; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.
    Peng LC; Narang AK; Gergis C; Radwan NA; Han P; Marciscano AE; Robertson SP; He P; Trieu J; Ram AN; McNutt TR; Griffith E; DeWeese TA; Honig S; Singh H; Greco SC; Tran PT; Deville C; DeWeese TL; Song DY
    Urol Oncol; 2018 Jun; 36(6):309.e7-309.e14. PubMed ID: 29551548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer.
    D'Amico AV; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):679-84. PubMed ID: 11172949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer.
    Pinover WH; Hanlon AL; Horwitz EM; Hanks GE
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):649-54. PubMed ID: 10837947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Renshaw AA; Tomaszewski JE; Richie JP; Wein A
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1227-33. PubMed ID: 10613317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
    Urology; 2005 Nov; 66(5):1048-53. PubMed ID: 16286122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.